Migraine treatment in developmental age: guidelines update

Area of Science:

• Neurology
• Pediatrics
• Pharmacology

Background:

• Limited controlled studies exist for pharmacological treatment of primary migraine in developmental age.
• Pediatric migraine patients exhibit higher placebo responses and spontaneous remission rates than adults.
• Designing randomized controlled trials (RCTs) for pediatric migraine is challenging due to shorter attack durations and unique clinical features.

Purpose of the Study:

• To summarize and update recent treatment guidelines for primary migraine in children and adolescents.
• To incorporate findings from recent research, including RCTs, controlled trials, and meta-analyses.
• To address the need for evidence-based approaches in this under-researched area.

Main Methods:

• Systematic review and synthesis of recent guidelines from major headache societies (Italian, French, American).
• Inclusion of data from RCTs, clinical controlled trials, open-label studies, meta-analyses, and reviews published since 2004.
• Consideration of pilot non-controlled studies, case series, and expert opinions due to limited strong evidence.

Main Results:

• Guidelines from the Italian Society for the Study of Headache, French Society for the Study of Migraine and Headache, and American Academy of Neurology were reviewed.
• Recent RCTs and other study types were integrated to inform treatment recommendations.
• Evidence was classified, and recommendations were categorized by level.

Conclusions:

• There is a critical need for updated, evidence-based guidelines for pediatric migraine treatment.
• The review provides a consolidated resource for clinicians managing primary migraine in children and adolescents.
• Further research is warranted to strengthen the evidence base for pediatric migraine pharmacotherapy.